spacer
home > ebr > spring 2019 > trusting in biobanking
PUBLICATIONS
European Biopharmaceutical Review

Trusting in Biobanking

Biobanking is used to create large scale repositories of human biological material, such as blood, urine, tissue, and DNA, to further medical research. Research institutes, hospitals, and biopharmaceutical and biotechnology companies rely on biobanks to advance research of new therapies and for the identification of disease biomarkers from large patient cohorts. Biobanking supports a number of modern research techniques, including genomics and personalised medicine, by allowing researchers to better understand who is most at risk of certain diseases and what treatments they may best respond to. A number of biobanks exist worldwide, each containing hundreds of thousands of samples to contribute to the growing pool of knowledge and safeguarding public health in future generations.

Nuclear Magnetic Resonance and Biobanking

Sample collection, preparation, analysis, storage, transport, and data management must all be highly standardised in biobanking. Samples that are stored over decades can change, and researchers can never guarantee that a sample will remain unchanged over time. The high reproducibility of nuclear magnetic resonance (NMR) spectroscopy makes it an important analytical tool for biobank samples. It can characterise stored samples and determine whether any changes could lead to artefacts.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Matthias Nauck is a Professor at the Institute of Clinical Chemistry at University Medicine Greifswald, Germany. His role is split between a focus on patient care and a range of scientific research projects. Matthias has played an integral role in introducing NMR to the lab at Greifswald for epidemiological research and biobanking studies.
spacer
Matthias Nauck
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

[Pamplona, November 26 2019] 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment.
More info >>

White Papers

Igb Tamper Evident Folding Box

IGB

The easiest, safest and less expensive solution in compliance with what requires Dir. 62/2011/EU, FDA and TGA.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement